GRAIL INC (GRAL) competitors & alternatives
Health Care · NASDAQ
GRAIL INC (GRAL)'s top competitors and alternatives — its most similar public companies — include Guardant Health, Inc. (GH), ARROWHEAD PHARMACEUTICALS, INC. (ARWR), BillionToOne, Inc. (BLLN), Natera (NTRA), MYRIAD GENETICS INC (MYGN), PERSONALIS INC (PSNL), VERACYTE INC (VCYT), LUCID DIAGNOSTICS INC (LUCD), Tempus AI (TEM), GENEDX HOLDINGS CORP CLASS A (WGS), BIODESIX INC (BDSX) and QUANTERIX CORP (QTRX). These are GRAIL INC's closest public-company peers by sub-industry, sector and business themes and is informational only — not financial advice.
Top GRAL competitors & alternatives
-
Guardant Health, Inc.GHHealth Care
Guardant Health is a precision oncology company transforming cancer care with FDA-approved blood and tissue tests powered by AI analytics that span early…
$150.75 (as of 2026-07-22) · market cap $19.8B
-
ARROWHEAD PHARMACEUTICALS, INC.ARWRHealth Care
A clinical-stage biotechnology company pioneering RNA interference (RNAi) therapeutics to treat a wide array of genetic and chronic diseases by silencing…
$88.70 (as of 2026-07-22) · market cap $13.0B
-
BillionToOne, Inc.BLLNHealth Care
BillionToOne uses breakthrough single-molecule sequencing technology to detect sparse disease signals in blood with unprecedented precision for prenatal and…
$129.24 (as of 2026-07-22) · market cap $6.0B
-
NateraNTRAHealth Care
Natera uses proprietary blood-based cell-free DNA technology to deliver personalized genetic diagnostics for oncology, prenatal screening, and organ transplant…
$264.22 (as of 2026-07-22) · market cap $37.9B
-
MYRIAD GENETICS INCMYGNHealth Care
Myriad Genetics is a molecular diagnostics and precision medicine company that develops genetic tests for cancer screening, therapy selection, prenatal health,…
$5.66 (as of 2026-07-22) · market cap $547M
-
PERSONALIS INCPSNLHealth Care
A genomic testing company enabling precision oncology through ultra-sensitive liquid biopsy and tumor sequencing to detect cancer recurrence and guide…
$12.47 (as of 2026-07-22) · market cap $1.3B
-
VERACYTE INCVCYTHealth Care
Veracyte is a genomics-focused diagnostics company providing high-value clinical tests to improve cancer detection and treatment guidance for patients…
$58.01 (as of 2026-07-22) · market cap $4.8B
-
LUCID DIAGNOSTICS INCLUCDHealth Care
Lucid Diagnostics develops EsoGuard, the first noninvasive DNA test for early detection of esophageal cancer precursors in millions of chronic GERD patients at…
$0.94 (as of 2026-07-22) · market cap $192M
-
Tempus AITEMHealth Care
Tempus AI leverages genomic sequencing, clinical data aggregation, and machine learning to deliver precision oncology diagnostics and AI-powered treatment…
$46.96 (as of 2026-07-22) · market cap $8.4B
-
GENEDX HOLDINGS CORP CLASS AWGSHealth Care
GeneDx is a genomic intelligence platform using whole-genome sequencing and AI-powered interpretation to diagnose rare diseases, analyze cancers, and support…
$62.60 (as of 2026-07-22) · market cap $1.9B
-
BIODESIX INCBDSXHealth Care
Biodesix develops precision diagnostic tests powered by molecular and AI analysis to guide oncology treatment decisions for clinicians, payers, and…
$21.39 (as of 2026-07-22) · market cap $222M
-
QUANTERIX CORPQTRXHealth Care
Quanterix develops ultra-sensitive protein detection and spatial tissue analysis platforms for biomarker discovery and early disease diagnostics, with recent…
$3.84 (as of 2026-07-22) · market cap $181M
Not quite? Describe exactly what you want →
Peers are GRAIL INC's closest public companies by shared sub-industry, sector and business themes. See the full profile: GRAIL INC (GRAL).
Last updated 2026-07-22.
Informational only — NOT financial advice. Company data is sourced from SEC EDGAR + Finnhub and shown with its as-of date.